Vijay Ramakrishnan

Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

Vijay Ramakrishnan, Michael Timm, Janine Haug et al. · Oncogene · 2009 · 99 citations · Full text

Hematological Malignancy, Common Anti-myeloma Drugs, Significant Anti-myeloma Activity +6

MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma

Vijay Ramakrishnan, Stephen M. Ansell, Janine Haug et al. · Leukemia · 2011 · 73 citations

Hematological Malignancy, Lymphoid Neoplasia, Vitro Pre-clinical Activity +9

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

Vijay Ramakrishnan, Teresa K. Kimlinger, Jessica Haug et al. · American Journal of Hematology · 2010 · 60 citations · Full text

Immunology, Cell Death, Immunotherapy +17

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway

Vijay Ramakrishnan, Teresa K. Kimlinger, Jessica Haug et al. · PLoS ONE · 2012 · 57 citations · Full text

Immunology, Cell Death, Mtorc1 Inhibitor +20

Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma

Vijay Ramakrishnan, Utkarsh Painuly, Teresa K. Kimlinger et al. · Leukemia · 2014 · 54 citations · Full text

Hematological Malignancy, Apoptosis, Immunology +7